Indivior (INDV) Projected to Post Earnings on Thursday

Indivior (NASDAQ:INDV) is expected to be issuing its Q1 2025 quarterly earnings data before the market opens on Thursday, April 24th. Analysts expect Indivior to post earnings of $0.22 per share and revenue of $240.13 million for the quarter. Indivior has set its FY 2025 guidance at EPS.

Indivior (NASDAQ:INDV) last issued its quarterly earnings data on Thursday, February 20th. The company reported $0.32 EPS for the quarter, hitting analysts’ consensus estimates of $0.32. The company had revenue of $298.00 million for the quarter, compared to analysts’ expectations of $262.35 million. Indivior had a negative return on equity of 241.73% and a negative net margin of 3.96%. On average, analysts expect Indivior to post $1 EPS for the current fiscal year and $2 EPS for the next fiscal year.

Indivior Stock Performance

Shares of NASDAQ:INDV opened at $8.81 on Tuesday. The company has a market cap of $1.21 billion, a P/E ratio of -25.17 and a beta of 0.93. Indivior has a one year low of $7.33 and a one year high of $19.13. The business’s 50-day simple moving average is $9.48 and its 200 day simple moving average is $10.32.

Wall Street Analyst Weigh In

Several brokerages have recently weighed in on INDV. Rodman & Renshaw initiated coverage on shares of Indivior in a research note on Tuesday, January 28th. They issued a “buy” rating and a $16.00 target price for the company. RODMAN&RENSHAW upgraded Indivior to a “strong-buy” rating in a research note on Tuesday, January 28th. Finally, Piper Sandler lowered their price objective on Indivior from $16.00 to $13.00 and set an “overweight” rating for the company in a research note on Thursday, March 6th.

Indivior Company Profile

Indivior PLC, together with its subsidiaries, engages in the development, manufacture, and sale of buprenorphine-based prescription drugs for the treatment of opioid dependence and co-occurring disorders in the United States, the United Kingdom, and internationally. The company develops medicines to treat substance use disorders, serious mental illnesses, and opioid overdose.